Polyunsaturated fatty acids in inflammatory bowel diseases: A reappraisal of effects and therapeutic approaches

Inflammatory Bowel Diseases

Volumn 19, Issue 3, 2013, Pages 650-661

  Marion Letellier, Rachel ^a   Savoye, Guillaume ^a,b   Beck, Paul L ^c   Panaccione, Remo ^c   Ghosh, Subrata ^c  

^a UNIVERSITÉ DE ROUEN   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Crohn's disease; Innate immunity; Polyunsaturated fatty acids; PPAR ; TLR; Ulcerative colitis

Indexed keywords

INFLAMMASOME; PLACEBO; POLYUNSATURATED FATTY ACID;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; AUTOPHAGY; CLINICAL TRIAL; CROHN DISEASE; DIET; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENTERITIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; INTESTINE FLORA; LIPID METABOLISM; NONHUMAN; PAIN; PRIORITY JOURNAL; REVIEW; ULCERATIVE COLITIS;

CROHN DISEASE; DIET; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; HUMANS; IMMUNITY, INNATE; INTESTINES;

EID: 84876364466     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e3182810122     Document Type: Review

References (140)

1. Chapman-Kiddell CA, Davies PS, Gillen L, et al. Role of diet in the development of inflammatory bowel disease. Inflamm Bowel Dis. 2010; 16:137-151.
2. Shoda R, Matsueda K, Yamato S, et al. Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. Am J Clin Nutr. 1996;63:741-745.
3. Jantchou P, Morois S, Clavel-Chapelon F, et al. Animal protein intake and risk of inflammatory bowel disease: the E3N prospective study. Am J Gastroenterol. 2010;105:2195-2201.
4. Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol. 2011;106:563-573.
5. Blasbalg TL, Hibbeln JR, Ramsden CE, et al. Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century. Am J Clin Nutr. 2011;93:950-962.
6. Tjonneland A, Overvad K, Bergmann MM, et al. Linoleic acid, a dietary n-6 polyunsaturated fatty acid, and the aetiology of ulcerative colitis: a nested case-control study within a European prospective cohort study. Gut. 2009;58:1606-1611.
7. de Silva PS, Luben R, Shrestha SS, et al. 100 dietary oleic acid protects against the development of ulcerative colitis - a UK prospective cohort study using data from food diaries. Gastroenterology. 2010;138:S-18.
8. John S, Luben R, Shrestha SS, et al. Dietary n-3 polyunsaturated fatty acids and the aetiology of ulcerative colitis: a UK prospective cohort study. Eur J Gastroenterol Hepatol. 2011;22:602-606.
9. Schmitz G, Ecker J. The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res. 2008;47:147-155.
10. Rachmilewitz D, Ligumsky M, Haimovitz A, et al. Prostanoid synthesis by cultured peripheral blood mononuclear cells in inflammatory diseases of the bowel. Gastroenterology. 1982;82:673-679.
11. Sharon P, Stenson WF. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology. 1984;86: 453-460.
12. Hassan A, Ibrahim A, Mbodji K, et al. An alpha-linolenic acid-rich formula reduces oxidative stress and inflammation by regulating NF-kappaB in rats with TNBS-induced colitis. J Nutr. 2010;140:1714-1721.
13. Llor X, Pons E, Roca A, et al. The effects of fish oil, olive oil, oleic acid and linoleic acid on colorectal neoplastic processes. Clin Nutr. 2003;22:71-79.
14. Ibrahim A, Mbodji K, Hassan A, et al. Anti-inflammatory and antiangiogenic effect of long chain n-3 polyunsaturated fatty acids in intestinal microvascular endothelium. Clin Nutr. 2011;30:678-687.
15. Arita M, Ohira T, Sun YP, et al. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol. 2007;178:3912-3917.
16. Arita M, Yoshida M, Hong S, et al. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2, 4, 6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A. 2005;102:7671-7676.
17. Weylandt KH, Kang JX, Wiedenmann B, et al. Lipoxins and resolvins in inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:797-799.
18. Aliberti J, Hieny S, Reis e Sousa C, et al. Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity. Nat Immunol. 2002;3:76-82.
19. Wan M, Godson C, Guiry PJ, et al. Leukotriene B4/antimicrobial peptide LL-37 proinflammatory circuits are mediated by BLT1 and FPR2/ALX and are counterregulated by lipoxin A4 and resolvin E1. FASEB J. 2011; 25:1697-1705.
20. Gewirtz AT, Collier-Hyams LS, Young AN, et al. Lipoxin a4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J Immunol. 2002;168:5260-5267.
21. Cui T, Schopfer FJ, Zhang J, et al. Nitrated fatty acids: endogenous antiinflammatory signaling mediators. J Biol Chem. 2006;281:35686-35698.
22. Pizato N, Bonatto S, Piconcelli M, et al. Fish oil alters T-lymphocyte proliferation and macrophage responses in Walker 256 tumor-bearing rats. Nutrition. 2006;22:425-432.
23. Draper E, Reynolds CM, Canavan M, et al. Omega-3 fatty acids attenuate dendritic cell function via NF-[kappa]B independent of PPAR [gamma]. J Nutr Biochem. 2011;22:784-790.
24. Marion-Letellier R, Butler M, Dechelotte P, et al. Comparison of cytokine modulation by natural peroxisome proliferator-activated receptor gamma ligands with synthetic ligands in intestinal-like Caco-2 cells and human dendritic cells-potential for dietary modulation of peroxisome proliferator-activated receptor gamma in intestinal inflammation. Am J Clin Nutr. 2008;87:939-948.
25. Ramakers JD, Mensink RP, Schaart G, et al. Arachidonic acid but not eicosapentaenoic acid (EPA) and oleic acid activates NF-kappaB and elevates ICAM-1 expression in Caco-2 cells. Lipids. 2007;42:687-698.
26. Harvey KA, Walker CL, Xu Z, et al. Oleic acid inhibits stearic acidinduced inhibition of cell growth and pro-inflammatory responses in human aortic endothelial cells. J Lipid Res. 2010;51:3470-3480.
27. Wang D, Wang H, Brown J, et al. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J ExpMed. 2006;203:941-951.
28. Scaldaferri F, Vetrano S, Sans M, et al. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology. 2009;136:585-595 e585.
29. Nakamoto K, Nishinaka T, Mankura M, et al. Antinociceptive effects of docosahexaenoic acid against various pain stimuli in mice. Biol Pharm Bull. 2010;33:1070-1072.
30. Blackshaw LA, Brierley SM, Hughes PA. TRP channels: new targets for visceral pain. Gut. 2010;59:126-135.
31. Akbar A, Yiangou Y, Facer P, et al. Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain. Gut. 2010;59:767-774.
32. Matta JA, Miyares RL, Ahern GP. TRPV1 is a novel target for omega-3 polyunsaturated fatty acids. J Physiol. 2007;578:397-411.
33. Brierley SM, Hughes PA, Page AJ, et al. The ion channel TRPA1 is required for normal mechanosensation and is modulated by algesic stimuli. Gastroenterology. 2009;137:2084-2095.e2083.
34. D'Aldebert E, Cenac N, Rousset P, et al. Transient receptor potential vanilloid 4 activated inflammatory signals by intestinal epithelial cells and colitis in mice. Gastroenterology. 2011;140:275-285.e273.
35. Bang S, Yoo S, Yang TJ, et al. Resolvin D1 attenuates activation of sensory transient receptor potential channels leading to multiple antinociception. Br J Pharmacol. 2010;161:707-720.
36. Gadaleta RM, van Erpecum KJ, Oldenburg B, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut. 2011;60:463-472.
37. Cattin AL, Le Beyec J, Barreau F, et al. Hepatocyte nuclear factor 4alpha, a key factor for homeostasis, cell architecture, and barrier function of the adult intestinal epithelium. Mol Cell Biol. 2009;29:6294-6308.
38. Ponferrada A, Caso JR, Alou L, et al. The role of PPAR[gamma] on restoration of colonic homeostasis after experimental stress-induced inflammation and dysfunction. Gastroenterology. 2007;132:1791-1803.
39. Kliewer SA, Sundseth SS, Jones SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A. 1997;94:4318-4323.
40. Schopfer FJ, Lin Y, Baker PR, et al. Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. Proc Natl Acad Sci U S A. 2005;102:2340-2345.
41. Lee JW, Bajwa PJ, Carson MJ, et al. Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10- deficient mice. Gastroenterology. 2007;133:108-123.
42. Bassaganya-Riera J, Reynolds K, Martino-Catt S, et al. Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology. 2004; 127:777-791.
43. Dubuquoy L, Jansson EA, Deeb S, et al. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology. 2003;124:1265-1276.
44. Sugawara K, Olson TS, Moskaluk CA, et al. Linkage to peroxisome proliferator-activated receptor-[gamma] in SAMP1/YitFc mice and in human Crohn's disease. Gastroenterology. 2005;128:351-360.
45. Desreumaux P, Dubuquoy L, Nutten S, et al. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med. 2001;193: 827-838.
46. Lewis JD, Lichtenstein GR, Deren JJ, et al. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology. 2008;134:688-695.
47. Milestone AN, Iacucci M, Ghosh S. Is rosiglitazone a promising treatment for ulcerative colitis? Nat Clin Pract Gastroenterol Hepatol. 2008; 5:486-487.
48. Peyrin-Biroulet L, Beisner J, Wang G, et al. Peroxisome proliferatoractivated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci U S A. 2011;107:8772-8777.
49. Yuan X, Ta TC, Lin M, et al. Identification of an endogenous ligand bound to a native orphan nuclear receptor. PLoS One. 2009;4:e5609.
50. Ahn SH, Shah YM, Inoue J, et al. Hepatocyte nuclear factor 4alpha in the intestinal epithelial cells protects against inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:908-920.
51. Zhong W, Zhao Y, McClain CJ, et al. Inactivation of hepatocyte nuclear factor-4{alpha. mediates alcohol-induced downregulation of intestinal tight junction proteins. Am J Physiol Gastrointest Liver Physiol. 2010; 299:G643-651.
52. Stegmann A, Hansen M, Wang Y, et al. Metabolome, transcriptome, and bioinformatic cis-element analyses point to HNF-4 as a central regulator of gene expression during enterocyte differentiation. Physiol Genomics. 2006;27:141-155.
53. Andersen V, Christensen J, Ernst A, et al. Polymorphisms in NF-kappaB, PXR, LXR, PPARgamma and risk of inflammatory bowel disease. World J Gastroenterol. 2011;17:197-206.
54. Zhou C, Tabb MM, Nelson EL, et al. Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. J Clin Invest. 2006;116:2280-2289.
55. Inoue J, Satoh S-i Kita M, et al. PPAR[alpha] gene expression is up-regulated by LXR and PXR activators in the small intestine. Biochem Biophys Res Commun. 2008;371:675-678.
56. Oh DY, Lagakos WS. The role of G-protein-coupled receptors in mediating the effect of fatty acids on inflammation and insulin sensitivity. Curr Opin Clin Nutr Metabol Care. 2011;14:322-327.
57. Oh DY, Talukdar S, Bae EJ, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142:687-698.
58. Bamba T, Shimoyama T, Sasaki M, et al. Dietary fat attenuates the benefits of an elemental diet in active Crohn's disease: a randomized, controlled trial. Eur J Gastroenterol Hepatol. 2003;15:151-157.
59. Gassull MA, Fernandez-Banares F, Cabre E, et al. Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a double blind randomised multicentre European trial. Gut. 2002;51:164-168.
60. Grogan JL, Casson DH, Terry A, et al. Enteral feeding therapy for newly diagnosed pediatric crohn's disease: a double-blind randomized controlled trial with two years follow-up. Inflamm Bowel Dis. 2012;18:246-253.
61. Feagan BG, Sandborn WJ, Mittmann U, et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA. 2008;299:1690-1697.
62. De Ley M, de Vos R, Hommes DW, et al. Fish oil for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007: CD005986.
63. Turner D, Shah PS, Steinhart AH, et al. Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): A systematic review and meta-analyses. Inflamm Bowel Dis. 2011;17:336-345.
64. Knoch B, Barnett MPG, Cooney J, et al. Dietary oleic acid as a control fatty acid for polyunsaturated fatty acid intervention studies: a transcriptomics and proteomics investigation using interleukin-10 gene-deficient mice. Biotechnol J. 2010;5:1226-1240.
65. Uchiyama K, Nakamura M, Odahara S, et al. N-3 polyunsaturated fatty acid diet therapy for patients with inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:1696-1707.
66. Cockbain AJ, Toogood GJ, Hull MA. Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer. Gut. 2012;61: 135-141.
67. Grimble RF, Howell WM, O'Reilly G, et al. The ability of fish oil to suppress tumor necrosis factor alpha production by peripheral blood mononuclear cells in healthy men is associated with polymorphisms in genes that influence tumor necrosis factor alpha production. Am J Clin Nutr. 2002;76:454-459.
68. Fontaine-Bisson B, Wolever TM, Chiasson JL, et al. Genetic polymorphisms of tumor necrosis factor-alpha modify the association between dietary polyunsaturated fatty acids and fasting HDL-cholesterol and apo A-I concentrations. Am J Clin Nutr. 2007;86:768-774.
69. Paradis AM, Fontaine-Bisson B, Bosse Y, et al. The peroxisome proliferator- activated receptor alpha Leu162Val polymorphism influences the metabolic response to a dietary intervention altering fatty acid proportions in healthy men. Am J Clin Nutr. 2005;81:523-530.
70. Guerreiro CS, Ferreira P, Tavares L, et al. Fatty acids, IL6, and TNFalpha polymorphisms: an example of nutrigenetics in Crohn's disease. Am J Gastroenterol. 2009;104:2241-2249.
71. Ferreira P, Cravo M, Guerreiro CS, et al. Fat intake interacts with polymorphisms of Caspase9, FasLigand and PPARgamma apoptotic genes in modulating Crohn's disease activity. Clin Nutr. 2011;29: 819-823.
72. Camuesco D, Comalada M, Concha A, et al. Intestinal anti-inflammatory activity of combined quercitrin and dietary olive oil supplemented with fish oil, rich in EPA and DHA (n-3) polyunsaturated fatty acids, in rats with DSS-induced colitis. Clin Nutr. 2006;25:466-476.
73. Camuesco D, Galvez J, Nieto A, et al. Dietary olive oil supplemented with fish oil, rich in EPA and DHA (n-3) polyunsaturated fatty acids, attenuates colonic inflammation in rats with DSS-induced colitis. J Nutr. 2005;135:687-694.
74. Collie-Duguid ES, Wahle KW. Inhibitory effect of fish oil N-3 polyunsaturated fatty acids on the expression of endothelial cell adhesion molecules. Biochem Biophys Res Commun. 1996;220:969-974.
75. Hugot J-P, Chamaillard M, Zouali H, et al. Association of NOD2 leucine- rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599-603.
76. Cario E. Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis. 2010;16:1583-1597.
77. Hedin CRH, Mullard M, Sharratt E, et al. Probiotic and prebiotic use in patients with inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2010;16:2099-2108.
78. Marteau P, Lemann M, Seksik P, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut. 2006;55:842-847.
79. Doherty GA, Bennett GC, Cheifetz AS, et al. Meta-analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn's disease. Aliment Pharmacol Ther. 2010;31:802-809.
80. Fava F, Danese S. Intestinal microbiota in inflammatory bowel disease: friend of foe? World J Gastroenterol. 2011;17:557-566.
81. Asakura H, Suzuki K, Kitahora T, et al. Is there a link between food and intestinal microbes and the occurrence of Crohn's disease and ulcerative colitis? J Gastroenterol Hepatol. 2008;23:1794-1801.
82. De Filippo C, Cavalieri D, Di Paola M, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A. 2010;107:14691-14696.
83. de La Serre CB, Ellis CL, Lee J, et al. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am J Physiol Gastrointest Liver Physiol. 2010;299: G440-448.
84. Murphy EF, Cotter PD, Healy S, et al. Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut. 2010;59:1635-1642.
85. Martin FP, Sprenger N, Montoliu I, et al. Dietary modulation of gut functional ecology studied by fecal metabonomics. J Proteome Res. 2010;9:5284-5295.
86. Jansson J, Willing B, Lucio M, et al. Metabolomics reveals metabolic biomarkers of Crohn's disease. PLoS One. 2009;4:e6386.
87. Hekmatdoost A, Feizabadi MM, Djazayery A, et al. The effect of dietary oils on cecal microflora in experimental colitis in mice. Indian J Gastroenterol. 2008;27:186-189.
88. Knoch B, Nones K, Barnett MPG, et al. Diversity of caecal bacteria is altered in interleukin-10 gene-deficient mice before and after colitis onset and when fed polyunsaturated fatty acids. Microbiology. 2010;156: 3306-3316.
89. Suzuki T, Hara H. Dietary fat and bile juice, but not obesity, are responsible for the increase in small intestinal permeability induced through the suppression of tight junction protein expression in LETO and OLETF rats. Nutr Metab (Lond). 2010;7:19.
90. Willemsen LE, Koetsier MA, Balvers M, et al. Polyunsaturated fatty acids support epithelial barrier integrity and reduce IL-4 mediated permeability in vitro. Eur J Nutr. 2008;47:183-191.
91. Ferrer R, Moreno JJ. Role of eicosanoids on intestinal epithelial homeostasis. Biochem Pharmacol. 2010;80:431-438.
92. Li Q, Zhang Q, Wang M, et al. n-3 polyunsaturated fatty acids prevent disruption of epithelial barrier function induced by proinflammatory cytokines. Mol Immunol. 2008;45:1356-1365.
93. Zhao L, Kwon MJ, Huang S, et al. Differential modulation of Nods signaling pathways by fatty acids in human colonic epithelial HCT116 cells. J Biol Chem. 2007;282:11618-11628.
94. Lee JY, Plakidas A, Lee WH, et al. Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res. 2003;44:479-486.
95. Weatherill AR, Lee JY, Zhao L, et al. Saturated and polyunsaturated fatty acids reciprocally modulate dendritic cell functions mediated through TLR4. J Immunol. 2005;174:5390-5397.
96. Lu J, Jilling T, Li D, et al. Polyunsaturated fatty acid supplementation alters proinflammatory gene expression and reduces the incidence of necrotizing enterocolitis in a neonatal rat model. Pediatr Res. 2007;61: 427-432.
97. Bertin B, Desreumaux P, Dubuquoy L. Obesity, visceral fat and Crohn's disease. Curr Opin Clin Nutr Metab Care. 2010;13:574-580.
98. Long MD, Crandall WV, Leibowitz IH, et al. Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:2162-2168.
99. de Silva PS, Olsen A, Christensen J, et al. An association between dietary arachidonic acid, measured in adipose tissue, and ulcerative colitis. Gastroenterology. 2010;139:1912-1917.
100. Schaeffler A, Gross P, Buettner R, et al. Fatty acid-induced induction of Toll-like receptor-4/nuclear factor-kappaB pathway in adipocytes links nutritional signalling with innate immunity. Immunology. 2009; 126:233-245.
101. Kalupahana NS, Claycombe K, Newman SJ, et al. Eicosapentaenoic acid prevents and reverses insulin resistance in high-fat diet-induced obese mice via modulation of adipose tissue inflammation. J Nutr. 2010;140: 1915-1922.
102. Hudert CA, Weylandt KH, Lu Y, et al. Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci U S A. 2006;103:11276-11281.
103. Smith BK, Holloway GP, Reza-Lopez S, et al. A decreased n-6/n-3 ratio in the fat-1 mouse is associated with improved glucose tolerance. Appl Physiol Nutr Metab. 2010;35:699-706.
104. Homer CR, Richmond AL, Rebert NA, et al. ATG16L1 and NOD2 interact in an autophagy-dependent antibacterial pathway implicated in Crohn's disease pathogenesis. Gastroenterology. 2010;139:1630-1641.
105. Kaser A, Blumberg RS. Autophagy, microbial sensing, endoplasmic reticulum stress, and epithelial function in inflammatory bowel disease. Gastroenterology. 2011;140:1738-1747.e1732.
106. Komiya K, Uchida T, Ueno T, et al. Free fatty acids stimulate autophagy in pancreatic [beta]-cells via JNK pathway. Biochem Biophys Res Commun. 2010;401:561-567.
107. Roberts RL, Topless RKG, Phipps-Green AJ, et al. Evidence of interaction of CARD8 rs2043211 with NALP3 rs35829419 in Crohn's disease. Genes Immun. 2010;11:351-356.
108. Hirota SA, Ng J, Lueng A, et al. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm Bowel Dis. 2011;17: 1359-1372.
109. Zaki MH, Boyd KL, Vogel P, et al. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity. 2010;32:379-391.
110. Elinav E, Strowig T, Kau Andrew L, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell. 2011; 145:745-757.
111. Ng J, Hirota SA, Gross O, et al. Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome. Gastroenterology. 2010;139:542-552.e543.
112. Flach TL, Ng G, Hari A, et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med. 2011;17: 479-487.
113. Muruve DA, Petrilli V, Zaiss AK, et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature. 2008;452:103-107.
114. Joosten LAB, Netea MG, Mylona E, et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1b production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum. 2010;62:3237-3248.
115. Wen H, Gris D, Lei Y, et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol. 2011; 12:408-415.
116. Zhou R, Tardivel A, Thorens B, et al. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol. 2011; 11:136-140.
117. Vandanmagsar B, Youm Y-H, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 2011;17:179-188.
118. Csak T, Ganz M, Pespisa J, et al. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology. 2011;54:133-144.
119. Leavy O. Innate immunity: linking lipids and inflammasomes. Nat Rev Immunol. 2010;11:368-369.
120. Wen H, Gris D, Lei Y, et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol. 2011;12:408-415.
121. Csak T, Ganz M, Pespisa J, et al. Fatty acids and endotoxin activate inflammasome in hepatocytes which release danger signals to activate immune cells in steatohepatitis. Hepatology. 2011;54:133-144.
122. Im SS, Yousef L, Blaschitz C, et al. Linking lipid metabolism to the innate immune response in macrophages through sterol regulatory element binding protein-1a. Cell Metab. 2011;13:540-549.
123. Ahmed T, Rieder F, Fiocchi C, et al. Pathogenesis of postoperative recurrence in Crohn's disease. Gut. 2011;60:553-562.
124. Doherty G, Bennett G, Patil S, et al. Interventions for prevention of postoperative recurrence of Crohn's disease. Cochrane Database Syst Rev. 2009:CD006873.
125. Jowett SL, Seal CJ, Pearce MS, et al. Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. Gut. 2004;53:1479-1484.
126. Grimstad T, Berge RK, Bohov P, et al. Salmon diet in patients with active ulcerative colitis reduced the simple clinical colitis activity index and increased the anti-inflammatory fatty acid index-a pilot study. Scand J Clin Lab Invest. 2011;71:68-73.
127. Shoda R, Matsueda K, Yamato S, et al. Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. Am J Clin Nutr. 1996;63:741-745.
128. John Sa, Luben Rb, Shrestha SSb, et al. Dietary n-3 polyunsaturated fatty acids and the aetiology of ulcerative colitis: a UK prospective cohort study. Eur J Gastroenterol Hepatol. 2010;22:602-606.
129. Heimerl S, Moehle C, Zahn A, et al. Alterations in intestinal fatty acid metabolism in inflammatory bowel disease. Biochim Biophys Acta. 2006; 1762:341-350.
130. Nishida T, Miwa H, Shigematsu A, et al. Increased arachidonic acid composition of phospholipids in colonic mucosa from patients with active ulcerative colitis. Gut. 1987;28:1002-1007.
131. Ueda Y, Kawakami Y, Kunii D, et al. Elevated concentrations of linoleic acid in erythrocyte membrane phospholipids in patients with inflammatory bowel disease. Nutr Res. 2008;28:239-244.
132. Singer II, Kawka DW, Schloemann S, et al. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology. 1998;115:297-306.
133. Sharon P, Ligumsky M, Rachmilewitz D, et al. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology. 1978;75:638-640.
134. Ikehata A, Hiwatashi N, Kinouchi Y, et al. Altered leukotriene B4 metabolism in colonic mucosa with inflammatory bowel disease. Scand J Gastroenterol. 1995;30:44-49.
135. Coste A, Dubuquoy L, Barnouin R, et al. LRH-1-mediated glucocorticoid synthesis in enterocytes protects against inflammatory bowel disease. Proc Natl Acad Sci U S A. 2007;104:13098-13103.
136. Peyrin-Biroulet L, Chamaillard M, Gonzalez F, et al. Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander? Gut. 2007;56:577-583.
137. Woodworth HL, McCaskey SJ, Duriancik DM, et al. Dietary fish oil alters T lymphocyte cell populations and exacerbates disease in a mouse model of inflammatory colitis. Cancer Res. 2010;70:7960-7969.
138. Hegazi RAF, Saad RS, Mady H, et al. Dietary fatty acids modulate chronic colitis, colitis-associated colon neoplasia and COX-2 expression in IL-10 knockout mice. Nutrition. 2006;22:275-282.
139. Matsunaga H, Hokari R, Kurihara C, et al. Omega-3 fatty acids exacerbate DSS-induced colitis through decreased adiponectin in colonic subepithelial myofibroblasts. Inflamm Bowel Dis. 2008;14:1348-1357.
140. Knoch B, Barnett MPG, McNabb WC, et al. Dietary arachidonic acidmediated effects on colon inflammation using transcriptome analysis. Mol Nutr Food Res. 2010;54:S62-S74.